Clinical Trials
Sage is committed to developing novel medicines to treat life-altering CNS disorders.
We are exploring new ways to think about and treat central nervous system (CNS) disorders. Our trials evaluate the safety and efficacy of our novel drug candidates in the disorders we study with the hope of potentially addressing gaps in available treatment options for these debilitating diseases. To rapidly advance our clinical development programs, we design efficient studies to look for profound therapeutic effects.
POSTPARTUM DEPRESSION
The Robin Study
Pivotal trial evaluating an oral therapeutic candidate in the treatment of postpartum depression.
This research study is evaluating the safety and effectiveness of SAGE-217, an investigational oral medication, in women with postpartum depression (PPD). For more information about this trial and participating locations, visit the Robin Study website.
We are committed to respecting the primary role of healthcare providers in the treatment of CNS disorders. Therefore, we cannot respond to medical questions about your personal health situation, nor can we accept private medical information. Please contact your healthcare provider with any questions pertaining to your or a family member’s medical condition.